SethOFagbemiMD

Oncology • Marshfield, WI

Clinical Assistant Professor, Department of Medicine-University of Wisconsin School of Medicine and Public Health Madison, WI

Join to view full profile

Dr. Fagbemi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fagbemi's full profile

Already have an account?

Office
1000 N Oak Ave
Marshfield, WI 54449
Phone+1 715-387-5426

Fax+1 715-221-8940

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1998
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1992 - 1995
University of IbadanClass of 1982

Certifications & Licensure

WI State Medical License 1993 - 2025
MI State Medical License 1998 - 2009
IL State Medical License 1992 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
ACTIVE_NOT_RECRUITING
PHASE3
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
ACTIVE_NOT_RECRUITING
PHASE3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
ACTIVE_NOT_RECRUITING
PHASE2
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31
Active, not recruiting
Phase 2
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Start of enrollment: 2020 Mar 03
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

3 citations
Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC)
Adedayo A. Onitilo, Trista J. Stankowski-Drengler, Oyewale Shiyanbola, Jessica M. Engel, Sabo Tanimu
Clinical Medicine & Research. 2021-03-31
5 citations
Community experience with bortezomib in patients with multiple myeloma.
Adedayo A. Onitilo, Jessica M. Engel, Bankole Olatosi, Seth O. Fagbemi
American Journal of Hematology. 2007-07-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member